At a glance
- Originator Encysive Pharmaceuticals
- Class Anti-ischaemics; Heart failure therapies
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pulmonary hypertension
Most Recent Events
- 23 Aug 2006 Discontinued - Preclinical for Pulmonary hypertension in USA (PO)
- 06 Jun 2006 No development reported - Preclinical for Pulmonary hypertension in USA (PO)
- 21 May 2003 Texas Biotechnology Corporation is now called Encysive Pharmaceuticals